PAPILLOCATION

Vaginal gel

Description
Gel for the prevention and adjuvant treatment of lesions caused by human papillomavirus (HPV).
- Creates a defensive barrier that prevents the risk of HPV integration and the formation of new lesions.
- Adjuvant in the re-epithelialization of existing lesions.
- Stimulates the regeneration of the vaginal microbiota.
Papilocare is indicated for:
- monitoring and re-epithelialization of the cervical transformation area to prevent the risk of lesions (LSIL) caused by HPV;
- adjuvant treatment of intraepithelial lesions caused by HPV;
- repairs and helps re-epithelialize lesions of the cervico-vaginal mucosa;
- treats dryness of the cervicovaginal mucosa;
- rebalances the vaginal microbiota;
- improves vaginal health;
- creates conditions for rapid healing of injuries caused by friction due to burns or itching;
- forms a protective film that quickly reduces discomfort, creating the right conditions to promote the natural healing process.
The main components of the formulation are:
- substances that allow the formation of a mucoadhesive gel on the cervico-vaginal mucosa, creating a protective film on it that favors the barrier action of the product;
- hyaluronic acid niosomes, with a moisturizing action on tissues, which helps maintain their elasticity;
- beta-glucan niosomes: due to their antioxidant properties, they maintain the natural structure and functionality of the skin and mucous membranes;
- Phytosomes of Centella asiatica, with a repairing action on damaged mucous membranes;
- Coriolus versicolor extract, with reepithelializing and repairing action on cervico-vaginal lesions and microlesions;
- neem extract, with emollient properties that promote the natural healing process;
- BioEcolia, a prebiotic that stimulates the growth of beneficial bacterial flora and rebalances the microbiota in the cervico-vaginal area;
- aloe vera extract with moisturizing, re-epithelializing and repairing action on the cervico-vaginal area.
The use of Papilocare is recommended for women (adults) who are positive for the human papillomavirus (HPV), regardless of the presence of lesions caused by the virus (ASCUS or LSIL).

How to use
The duration of treatment is 6 months, with the possibility of a further extension depending on the doctor's prescription. It is important to complete the entire treatment cycle to achieve the desired results.
It is recommended to start treatment after the menstrual cycle.
First month: apply one cannula per day for 21 consecutive days, then discontinue treatment for the next 7 days.
Subsequent months (second to sixth): Apply one cannula every other day for 21 days.
Interrupting Papilocare treatment during the menstrual cycle is recommended only for the comfort of patients; in fact, there are no clinical incompatibilities.
Apply preferably before bedtime.
It is compatible with condom use.
Discard any open or broken cannula. The cannula is designed to facilitate administration of the product. Insert the cannula into the vagina and apply pressure to release the contents. Then, remove the cannula from the vagina, maintaining pressure so that it does not reabsorb the administered product.
Some gel may remain inside the cannula; this does not mean that a lower dose than recommended has been administered, as the cannula delivers enough gel to cover the cervicovaginal mucosa (3 ml). Discard the cannula after use. Do not reuse a used cannula or share it with other patients.

warnings
Keep out of reach of children.
If you are pregnant, consult your doctor.
Do not use in case of known hypersensitivity to any of its components.
If you experience discomfort after application, discontinue use of the product and consult a doctor.
There are no data available on the use of Papilocare with contraceptives (e.g. vaginal rings or female condoms), so Papilocare is not recommended for women using these types of contraceptives. If you are pregnant, consult your doctor before using Papilocare and use it under strict medical supervision.

Conservation
Store between 2°C and 25°C.
Shelf life in intact packaging: 42 months.

Format
Package contains 7 cannulas of 5 ml each.

Code 010/056